Ginkgo Bioworks Holdings Q2 2024 GAAP EPS $(0.11) Misses $(0.07) Estimate, Sales $56.21M Beat $43.14M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ginkgo Bioworks Holdings (NYSE:DNA) reported Q2 2024 GAAP EPS of $(0.11), missing the $(0.07) estimate, but achieved sales of $56.21M, beating the $43.14M estimate. Sales decreased by 30.24% compared to the same period last year.
August 08, 2024 | 9:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ginkgo Bioworks Holdings reported a Q2 2024 GAAP EPS of $(0.11), missing the $(0.07) estimate, but achieved sales of $56.21M, beating the $43.14M estimate. Sales decreased by 30.24% compared to the same period last year.
The mixed earnings report, with a significant EPS miss but a notable sales beat, creates a neutral short-term outlook. The EPS miss may concern investors, but the strong sales performance could offset some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100